Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 1/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | CCRL2 | O00421 | 4/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | FBP1 | P09467 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21657083 | 0.80 | OPRL1 (0.43) | OPRL1NR3C1CCR2KCNH2CCRL2 | |
| Alcohol SCHEMBL6978627 | 0.79 | OPRL1 (0.47) | OPRL1NR3C1CCR2KCNH2IRAK4 | |
| SCHEMBL12776380 | 0.78 | NPC1 (0.46) | OPRL1NR3C1CCR2KCNH2CCRL2 | |
| SCHEMBL17148512 | 0.78 | OPRL1 (0.47) | OPRL1NR3C1CCR2KCNH2CCRL2 | |
| Alcohol SCHEMBL6978770 | 0.78 | OPRL1 (0.46) | OPRL1NR3C1CCR2KCNH2IRAK4 | |
| SCHEMBL15823795 | 0.76 | SYK (0.44) | OPRL1KDM4EALDH1A1GAASMN1; SMN2 | |
| SCHEMBL1356638 | 0.76 | OPRL1 (0.53) | OPRL1CCR2KCNH2CCRL2IRAK4 | |
| SCHEMBL2500932 | 0.75 | OPRL1 (0.47) | OPRL1CCR2KCNH2CCRL2IRAK4 | |
| SCHEMBL15826397 | 0.75 | OPRL1 (0.47) | OPRL1CCR2KCNH2CCRL2IRAK4 | |
| SCHEMBL15826398 | 0.75 | OPRL1 (0.47) | OPRL1CCR2KCNH2CCRL2IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | OPRL1 2012/4885NR3C1 893/4885CCR2 1786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.